DOCETAXEL IN PREVIOUSLY TREATED SUBJECTS WITH LEIOMYOSARCOMA (ARGSARC): A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER PHASE 3 TRIAL

Registry ID

POLARIS2022-001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

POLARIS PHARMACEUTICALS, INC. (A SUBSIDIARY OF POLARIS GROUP)

Start date

2024-01-20

Last update

2023-09-26

Conditions

• LEIOMYOSARCOMA

View on source registry